(3,6-dimethylpyridin-2-yl)methanamine | 863548-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (3,6-dimethylpyridin-2-yl)methanamine
• CAS: 863548-40-7
• 化学式: C₈H₁₂N₂
• mdl: MFCD12401087
• 分子量: 136.197
• InChiKey: YBQLVYCNSLQITM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3,6-dimethylpyridin-2-yl)methanamine 、 2-amino-6-(5-methyl-2-furyl)-pyrimidine-4-carboxylic acid 在 polymer supported carbodiimide 、 1-羟基苯并三唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以11%的产率得到N-(3,6-dimethyl-pyridin-2-ylmethyl)-2-amino-6-(5-methyl-2-furyl)pyrimidine-4-carboxamide
  参考文献：
  名称：

  Antagonists of the human A2A receptor. Part 6: Further optimization of pyrimidine-4-carboxamides

  摘要：

  Antagonists of the human A(2A) receptor have been reported to have potential therapeutic benefit in the alleviation of the symptoms associated with neurodegenerative movement disorders such as Parkinson's disease. As part of our efforts to discover potent and selective antagonists of this receptor, we herein describe the detailed optimization and structure-activity relationships of a series of pyrimidine-4-carboxamides. These optimized derivatives display desirable physiochemical and pharmacokinetic profiles, which have led to promising oral activity in clinically relevant models of Parkinson's disease. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.07.078
• 作为产物：
  描述：

  2-氯-3,6-二甲基吡啶 在 盐酸 、 四(三苯基膦)钯 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0~130.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 生成 (3,6-dimethylpyridin-2-yl)methanamine
  参考文献：
  名称：

  [EN] AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
  [FR] COMPOSÉS AMINOPYRAZINES AYANT DES PROPRIÉTÉS ANTAGONISTES DE L'A2A

  摘要：

  公开的是Formula A和Formula A-1的化合物，或其盐，以及包含这些化合物或其盐的药物配方（药物组合物）；其中“R1”、“RA-1”、“R2”、“R3”和“Het”如上所定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度存在的受体。这些化合物和药物配方被认为在治疗或管理神经退行性疾病方面有用，例如帕金森病，或由于使用治疗或管理帕金森病的某些药物而引起的运动障碍。

  公开号：

  WO2016081290A1

文献信息

• PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL
  申请人：KANTO KAGAKU KABUSHIKI KAISHA

  公开号：US20150031920A1

  公开（公告）日：2015-01-29

  [Object] The object of this invention is to provide a method for producing an optically active secondary alcohol at a high optical purity by hydrogenating a substrate carbonyl compound at a high efficiency using as a catalyst a ruthenium complex bearing as a ligand certain optically active diphosphine compound and a readily synthesized amine compound. [Solution] The method of producing an optically active secondary alcohol according to the present invention is characterized in that a substrate carbonyl compound (provided that 3-quinuclidinone, 3-quinuclidinone derivative having a substituent, and a ketone having an aromatic hydrocarbon group and a heterocycle are excluded) is reacted with hydrogen and/or a hydrogen donating compound in the presence of a ruthenium complex selected from the compounds expressed by following general formula (1) RuXYAB (1) [in the general formula (1), X and Y are the same or different from each other and denote a hydrogen atom or an anionic group, A denotes an optically active diphosphine expressed by the general formula (2), B denotes an amine compound expressed by following general formula (3)].

  本发明的目的是提供一种通过在高效率下使用一种作为催化剂的钌配合物，其中该钌配合物携带某种光学活性的二膦化合物和一种易于合成的胺化合物，从而在高光学纯度下加氢化底物羰基化合物生产光学活性二级醇的方法。 根据本发明的一种生产光学活性二级醇的方法的特征在于，在一种选择自下述通用式（1）RuXYAB所表示的化合物的钌配合物的存在下，将底物羰基化合物（假设排除3-喹啉酮、带有取代基的3-喹啉酮衍生物以及具有芳香烃基和杂环的酮）与氢气和/或氢供体化合物反应。[在通用式（1）中，X和Y相同或不同，表示氢原子或阴离子基团，A表示由通用式（2）表示的光学活性二膦，B表示由下述通用式（3）表示的胺化合物]。
• Pyrimidine Compounds as Purine Receptor Antagonist
  申请人：Gillespie John Roger

  公开号：US20070281936A1

  公开（公告）日：2007-12-06

  Compounds of formula (I); wherein R 1 is H or NHZ; R 2 is optionally substituted aryl or heteroaryl attached via a carbon atom; R 3 is H; optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 C 7 cycloalkyl, halogen; OH or OR, or R 4 is H, optionally substituted C 1 -C 6 alkyl, C 3 C 6 alkenyl, C 3 -C 6 alkynyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl, R 5 is H or optionally substituted C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 alkynyl, or C 3 -C 7 cycloalkyl; or R 4 and R 5 together form a 5 or 6-membered heterocyclic ring; and R 10 is optionally substituted C 1 -C 6 alkyl; are purine receptor, particularly adenosine receptor antagonists, useful for treatment of, inter alia, movement disorders such as Parkinsons disease.

  化合物的公式（I）;其中R1是H或NHZ; R2是通过碳原子连接的可选取代芳基或杂环芳基; R3是H; 可选取代的C1-C6烷基，C2-C6烯基，C2-C6炔基或C3C7环烷基，卤素; OH或OR，或R4是H，可选取代的C1-C6烷基，C3C6烯基，C3-C6炔基，C3-C7环烷基，芳基或杂环芳基，R5是H或可选取代的C1-C6烷基，C3-C6烯基，C3-C6炔基或C3-C7环烷基; 或R4和R5一起形成5或6元杂环环; R10是可选取代的C1-C6烷基; 是嘌呤受体，特别是腺苷受体拮抗剂，用于治疗运动障碍，如帕金森病等。
• Pyrimidine compounds as purine receptor antagonist
  申请人：Vernalis (R&D) Limited

  公开号：US07875600B2

  公开（公告）日：2011-01-25

  Compounds of formula (I); wherein R1 is H or NHZ; R2 is optionally substituted aryl or heteroaryl attached via a carbon atom; R3 is H; optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, or C3 C7 cycloalkyl, halogen; OH or OR, or R4 is H, optionally substituted C1-C6alkyl, C3 C6alkenyl, C3-C6alkynyl, C3-C7 cycloalkyl, aryl or heteroaryl, R5 is H or optionally substituted C1-C6alkyl, C3-C6alkenyl, C3-C6alkynyl, or C3-C7 cycloalkyl; or R4 and R5 together form a 5 or 6-membered heterocyclic ring; and R10 is optionally substituted C1-C6alkyl; are purine receptor, particularly adenosine receptor antagonists, useful for treatment of, inter alia, movement disorders such as Parkinsons disease.

  式(I)化合物，其中R1为H或NHZ；R2为通过碳原子连接的可选取代芳基或杂环芳基；R3为H；可选取代的C1-C6烷基，C2-C6烯基，C2-C6炔基或C3-C7环烷基，卤素；OH或OR，或R4为H，可选取代的C1-C6烷基，C3-C6烯基，C3-C6炔基，C3-C7环烷基，芳基或杂环芳基，R5为H或可选取代的C1-C6烷基，C3-C6烯基，C3-C6炔基或C3-C7环烷基；或R4和R5共同形成5或6成员杂环环；R10为可选取代的C1-C6烷基。这些化合物是嘌呤受体，特别是腺苷受体拮抗剂，可用于治疗运动障碍症，如帕金森病等。
• Process for producing optically active secondary alcohol
  申请人：Kanto Kagaku Kabushiki Kaisha

  公开号：EP2865446A1

  公开（公告）日：2015-04-29

  The object of this invention is to provide a method for producing an optically active secondary alcohol at a high optical purity by hydrogenating a substrate carbonyl compound at a high efficiency using as a catalyst a ruthenium complex bearing as a ligand certain optically active diphosphine compound and a readily synthesized amine compound. The method of producing an optically active secondary alcohol according to the present invention is characterized in that a substrate carbonyl compound (provided that 3-quinuclidinone, 3-quinuclidinone derivative having a substituent, and a ketone having an aromatic hydrocarbon group and a heterocycle are excluded) is reacted with hydrogen and/or a hydrogen donating compound in the presence of a ruthenium complex selected from the compounds expressed by following general formula (1) RuXYAB (1) [in the general formula (1), X and Y are the same or different from each other and denote a hydrogen atom or an anionic group, A denotes an optically active diphosphine expressed by the general formula (2), B denotes an amine compound expressed by following general formula (3)].

  本发明的目的是提供一种高光学纯度的光学活性仲醇的制取方法，该方法是以某种光学活性二膦化合物和易于合成的胺化合物为配体的钌络合物为催化剂，通过高效率地氢化底物羰基化合物来制取光学活性仲醇。 根据本发明的生产光学活性仲醇的方法，其特征在于底物羰基化合物(但不包括3-奎宁环酮、具有取代基的3-奎宁环酮衍生物和具有芳香烃基和杂环的酮)在选自通式(1)RuXYAB(1)的化合物的钌络合物存在下与氢和/或氢捐赠化合物反应[在通式(1)中、X 和 Y 彼此相同或不同，表示氢原子或阴离子基团，A 表示通式 (2) 所表示的光学活性二膦，B 表示通式 (3) 所表示的胺化合物]。
• Aminopyrazine compounds with A2A antagonist properties
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10472347B2

  公开（公告）日：2019-11-12

  Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

  公开了式A和式A-1化合物或其盐，以及包含这些化合物或其盐的药物制剂（药物组合物）；其中 "R1"、"RA-1"、"R2"、"R3 "和 "Het "如上文所定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度存在的A2a受体。 此类化合物和药物制剂被认为可用于治疗或控制神经退行性疾病，例如帕金森病，或因使用某些用于治疗或控制帕金森病的药物而引起的运动障碍。